Canagliflozin Drug Market 2022 Size, Growth Analysis Report, Forecast to 2028
The canagliflozin drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Canagliflozin drug is prescribed in the treatment of type 2 diabetes. It lowers the blood sugar level in the body. A high concentration of blood sugar in the body is seen in type 2 diabetes. In this condition, the body lacks the production of insulin or functions it smoothly. Canagliflozin drug comes under a class of medication known as sodium-glucose cotransporter 2. This drug works on the kidneys to lower the sugar content which passes through urine. Type 2 diabetes is a chronic condition in which sugar circulation is increased in the bloodstream. High sugar content in the body leads to further ailments such as nervous and immune system disorders. Around 537 million adults were suffering from any type of diabetes globally in the year 2021.(Get 15% Discount on Buying this Report)
Click Here to Get a Free Sample Report of the Canagliflozin Drug Market @ https://orionmarketreports.com/request-sample/?id=109620&submit=Request+Sample%0D%0A
Canagliflozin drug is also prescribed for cardiovascular disease. These are disorders of the heart and bloodstream. Various conditions under cardiovascular disease are - coronary artery disease, cerebrovascular disease, peripheral arterial disease, and rheumatic heart disease. Coronary artery disease is a condition in which cholesterol deposits in the walls of the artery. These arteries supply blood to the heart from the body. Blocking of this artery causes the heart to pump more to pass the blood which puts a strain on the heart. Cerebrovascular disease is a condition in which smooth blood to the brain is hampered.
Scope of the Canagliflozin Drug Report
The research study analyzes the Canagliflozin Drug industry from a 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent Developments
Market Overview and growth analysis
Import and Export Overview
Volume Analysis
Current Market Trends and Future Outlook
Market Opportunistic and Attractive Investment Segment
A full report of Canagliflozin Drug Market is available at: https://orionmarketreports.com/canagliflozin-drug-market/109620/
Canagliflozin Drug Market Segmentation:
By Disease
Type 2 Diabetes
Cardiovascular Disease
End-Stage Renal Disease
By End-User
Hospital
Clinic
Others
Competitive Landscape- Janssen Global Services, LLC, Dr. Reddy's Laboratories Ltd., Mitsubishi Tanabe Pharma Corp.
Geographic Coverage
North America Market Size and/or Volume
Latin America Market Size and/or Volume
Europe Market Size and/or Volume
Asia-Pacific Market Size and/or Volume
Rest of the world Market Size and/or Volume
Key questions answered in this report:
What is the size of the Canagliflozin Drug market and what is its expected growth rate?
What are the primary driving factors that push the Canagliflozin Drug Market forward?
What are the Canagliflozin Drug Industry's top companies?
What are the different categories that the Canagliflozin Drug Market caters to?
What will be the fastest-growing segment or region?
In the value chain, what role do essential players play?
What is the procedure for getting a free copy of the Canagliflozin Drug Market sample report and company profiles?
The report covers the following objectives:
Proliferation and maturation of trade in the Canagliflozin Drug market.
The market share of the Canagliflozin Drug market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
Current and future market trends that are influencing the growth opportunities and growth rate of the Canagliflozin Drug market.
Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the Canagliflozin Drug market.
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
About Us:
Orion Market Reports (OMR) endeavor to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Canagliflozin Drug Market 2022 Size, Growth Analysis Report, Forecast to 2028 here
News-ID: 2636594 • Views: …
More Releases from orionmarketreports
Tumor Necrosis Factor Receptor Superfamily Member 9 Market Sluggish Growth Rate …
Tumor Necrosis Factor Receptor Superfamily Member 9 Market was valued at USD Billion in 2023 and is expected to grow at a CAGR of 26% between 2024 and 2031. Tumor Necrosis Factor Receptor Superfamily Member 9 Market research report is one of the effective ways to target customers and satisfy their growing needs as it gathers all the significant market data. It allows tracking future business growth for the forthcoming…
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market is Anticip …
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market was valued at USD Billion in 2023 and is expected to grow at a CAGR of 25% between 2024 and 2031. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market research report is one of the effective ways to target customers and satisfy their growing needs as it gathers all the significant market data. It allows tracking future business growth for…
C-X-C Chemokine Receptor Type 1 Market to Signify Strong Growth by 2024-2031
C-X-C Chemokine Receptor Type 1 Market was valued at USD Billion in 2023 and is expected to grow at a CAGR of 23% between 2024 and 2031. C-X-C Chemokine Receptor Type 1 Market research report is one of the effective ways to target customers and satisfy their growing needs as it gathers all the significant market data. It allows tracking future business growth for the forthcoming duration 2024-2031. It further…
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Ma …
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market was valued at USD Billion in 2023 and is expected to grow at a CAGR of 27% between 2024 and 2031. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market research report is one of the effective ways to target customers and satisfy their growing needs as it gathers all the significant market data. It allows tracking future business…
More Releases for Canagliflozin
Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Produc …
Canagliflozin is a medication used to treat type 2 diabetes. It is a third-line medication to be tried after metformin, a first-line medication for type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.
Mechanism action of Canagliflozin
Canagliflozin is a sodium-glucose cotransporter (SGLT2) inhibitor. Glucose filtered in the renal tubular lumen is mainly reabsorbed by SGLT2 expressed in the proximal renal…
Canagliflozin Hemihydrate Trends and Forecast Report 2022 | By Players, Types, A …
The QY Research released a latest market research report on the global and United States Canagliflozin Hemihydrate market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Canagliflozin Hemihydrate will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type…
Global Antidiabetic SGLT-2 Inhibitor Sales Market Size, Status Analysis, Growth …
The market for pharmaceutical industry growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Antidiabetic SGLT-2 Inhibitor Sales Market Size, Status Analysis, Growth & Forecast during 2018-2025”which offer details about the current trends as well as scope for the near future. This research study also covers information about the production and market share based on different active regions. Furthermore,…
Antidiabetic SGLT-2 Inhibitor Market Analysis- Size, Share, Growth, Industry Dem …
The Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2017 renders deep perception of the key regional market status of the Antidiabetic SGLT-2 Inhibitor Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan.
Request For Sample Of Antidiabetic SGLT-2 Inhibitor Market Research Report @ https://www.qyresearchgroups.com/request-sample/426283
The report on “Global…
Global Antidiabetic SGLT-2 Inhibitor Sales Industry Analysis, Growth, Demand, St …
Market Research Hub's report studies sales (consumption) of Global Antidiabetic SGLT-2 Inhibitor market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
Anderson Hay & Grain Inc.
Border Valley
Sanofi
Johnson & Johnson
Bristol-Myers Squibb
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline
Pfizer
Takeda Pharmaceuticals
Eli Lilly
Merck & Co.
Novo Nordisk
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=942289
Market Segment by Regions, this report splits Global into several key…
Diabetes and obesity therapeutics market will more than double to $163.2 billion …
Report Title: Global Diabetes and Obesity Drugs Market to 2022
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%.
Callum Dew, Associate Analyst for GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin)…